NOTE TO READERS: When this project lost substantial funding at the end of 2018, I lost the ability to continue publishing criteria-driven news story reviews and PR news release reviews - once the bread-and-butter of the site going back to 2006. The 3,200 archived reviews, while still educational, are getting old and difficult for me to technically maintain on the back end of the website. So I am announcing that I plan to remove these reviews from the site by April 1, 2021. The blog and the toolkit - two of the most popular features on the site - will remain. If you wish to peruse the reviews before they disappear, please do so by the end of March 2021. After that date you may still be able to access them via the Internet Archive Wayback Machine -

Tags: FDA


Without an independent source, BuzzFeed’s story on a medical device for OCD doesn’t offer much beyond the news release

5 10/25/2017

Brief but informative report from AP on newly approved shingles vaccine


Washington Post wisely notes that CAR T-cell therapy may cost at least $300,000


Lack of independent sources hinders AP story on new drug that treats side effect caused by antipsychotics


Tacos and neural tube defects: NPR deftly explains the connection

1 11/13/2015

WSJ whiffs on meaningful aspects of new melanoma drug approval — including $17,600/month price tag


Weight-Loss Drugs Face High Hurdles At FDA


FDA Approves Cystic Fibrosis Drug


FDA Approves New Device for Brain Tumor Treatment


FDA Approves First Drug To Prevent Preterm Births